Company: NOTV
Filing Date: 2025-01-23
Form Type: DEF 14A
Source: 0001628280-25-002250
Chunk: 20

Company: Inotiv, Inc.
Filing Date: 2025-01-23
Form: DEF 14A
Chunk 20
---
 U.K., and held the Nestlé post-doctoral fellowship at Massachusetts Institute of Technology. He is extensively published in scientific and business literature and has advised governments and companies on policy formulation related to pharmaceutical R&D. Dr. Brown’s current term on the Board expires at the 2026 Annual Meeting of Shareholders.

Terry Coelho joined the Company’s Board of Directors in October 2023. Ms. Coelho is the Executive Vice President and CFO and a member of the board of directors of HOOPIKA Pharma Inc., a public, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to fight cancer and chronic infectious disease. She has over 35 years’ experience as a business leader and senior executive, including more than 15 years in the biopharmaceutical sector with both multinational pharmaceutical and small biotechnology companies. Ms. Coelho previously served as the CFO of Gamida Cell Ltd., a public, commercial-stage biotechnology company focused on cell therapy, where she was instrumental

<div align='center'>12</div>

in navigating a successful exit for the company. Prior to that role, she served as Vice President, CFO and Chief Business Development Officer of CinCor Pharma, Inc., where she led the successful IPO in January 2022, followed by a follow-on offering, prior to its sale to AstraZeneca for approximately $1.8 billion. Her previous experience includes serving as CFO of BioDelivery Sciences International, Balchem Corporation and Diversey, the finance lead for Novartis’ oncology hematology franchise and Global Head of Oncology Development Finance at Novartis, as well as various positions of increasing responsibility within Mars, Inc. Prior to assuming the CFO role at HOOPIKA, Ms. Coelho served as the Audit Committee Chair and a member of the Compensation Committee for that company. She is a founding advisory board member of the CFO Leadership Council (Charlotte and Raleigh chapters) and has served on Northeastern University’s MBA Finance Track advisory board and the University of North Carolina Charlotte Women in Business advisory board. Within the past five years, Ms. Coelho served as a member of the board of directors of Entero Therapeutics, Inc. (formerly First Wave Biopharma, Inc.). Ms. Coelho received her M.B.A. in Finance from the Instituto Brasiliero do Mercado de Capitais (IBMEC) in Rio de Janeiro, and her B.A. in International Studies and Economics from the American University School of International Service in Washington